Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI305 vs Bevacizumab in Advanced or Recurrent Non-squamous NSCLC
CTR20160848Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Innovent Biologics. Started Nov 2016; status: active.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20160848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160848.